Corrigendum: Adjuvant bevacizumab for melanoma patients at high risk of recurrence: Survival analysis of the AVAST-M trial (Annals of Oncology (2018) 29:8 (1843-1852) DOI: 10.1093/annonc/mdy229)
Pippa Corrie,Andrea Marshall,Paul Nathan,Paul Lorigan,M. E. Gore,Saad Tahir,Guy Faust,Charles Kelly,Maria Marples,Sarah Danson,Ernie Marshall,Stephen Houston,Ruth E Board,Ashita Waterston,Jenny Nobes,Mark Harries,Shaji Kumar,Andrew Goodman,Angus G. Dalgleish,A. Martin-Clavijo,S. Westwell,R. Casasola,David Chao,Anthony Maraveyas,Poulam M. Patel,Christian H. Ottensmeier,David Farrugia,A. Humphreys,B.K. Eccles,Gemma Young,E. O. Barker,C. Harman,M. Weiss,Kevin A. Myers,A. Chhabra,Simon Rodwell,Janet A. Dunn,Mark R. Middleton +37 more
8
About: This article is published in Annals of Oncology. The article was published on 08 Jan 2020. and is currently open access. The article focuses on the topics: Bevacizumab.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Hypoxia-dependent drivers of melanoma progression
TL;DR: In this article, the latest progress in hypoxia-regulated pathways involved in the development and progression of all melanoma subtypes were discussed, and the authors summarized current knowledge on preclinical studies with drugs targeting HypoxiaInducible Factor-1, angiogenesis or vasculogenic mimicry.
Advances in the discovery and development of melanoma drug therapies
Monica Chanda,Mark S. Cohen +1 more
TL;DR: In this paper, a review of melanoma drug therapies and their applications in combination therapy regimens is presented, where the authors provide an overview of the preclinical mechanism of action, the clinical efficacy data, and their application in combination therapies.
14
The combinational nano-immunotherapy of ferumoxytol and poly(I:C) inhibits melanoma via boosting anti-angiogenic immunity.
Yunuo Zheng,Bo Jiang,Hongmei Guo,Zhonghai Zhang,Bo Chen,Zhengkui Zhang,Shaoyuan Wu,Jiaojiao Zhao +7 more
TL;DR: In this article , a nano-immunotherapy combining ferumoxytol and poly(I:C) was developed to boost the anti-angiogenic activities of macrophages to inhibit melanoma.
7
Unexpected “Lazarus response” to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer
Alexey V. Emshanov,D. Nesterov,Tatyana N. Sokolova,Priscilla S. Amankwah,Evgenii N. Imyanitov +4 more
TL;DR: Four cases of heavily pretreated patients with metastatic HER2-positive breast cancer, who had no meaningful treatment options left, and who received single-agent bevacizumab as an empirical last-resort therapy are described, and some evidence of a direct antitumor effect was observed.
1
Atypical primary malignant melanoma originating in the spinal canal: A case report and literature review
Ying Zeng,Yong Zhang,Jing Zhang,Wei Jiang,Rongqing Li,Qiangqiang Fu +5 more
TL;DR: Atypical primary malignant melanoma originating in the spinal canal is a rare tumor with limited treatment options. The majority of patients with primary malignant melanoma in the spinal canal have incompletely resected tumors and poor prognosis.